[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100455889":3},{"organization":4,"armGroups":7,"interventions":44,"overallOfficials":50,"centralContacts":82,"locations":88,"responsibleParty":432,"collaborators":50,"id":434,"slug":435,"hasResults":436,"nctId":437,"briefTitle":438,"officialTitle":438,"acronym":50,"eligibilityCriteria":439,"healthyVolunteers":436,"sex":440,"minAge":441,"maxAge":50,"enrollmentInfo":442,"targetDuration":50,"studyType":445,"phases":446,"briefSummary":448,"conditions":449,"keywords":50,"overallStatus":91,"whyStopped":50,"lastUpdateSubmitDate":457,"lastUpdatePostDateStruct":458,"startDateStruct":461,"completionDateStruct":463,"leadSponsor":465,"locationsCount":466},{"fullName":5,"class":6},"Relay Therapeutics, Inc.","INDUSTRY",[8,14,19,24,29,34,39],{"label":9,"type":10,"description":11,"interventionNames":12},"RLY-2608 for patients with unresectable or metastatic solid tumors","EXPERIMENTAL","Multiple doses of RLY-2608 for oral administration.",[13],"Drug: RLY-2608",{"label":15,"type":10,"description":16,"interventionNames":17},"RLY-2608 + fulvestrant combination for HR+ HER2- locally advanced or metastatic breast cancer","Oral dose of RLY-2608 in addition to fulvestrant as determined during Part 1 Dose Escalation.",[13,18],"Drug: Fulvestrant",{"label":20,"type":10,"description":21,"interventionNames":22},"RLY-2608+fulvestrant+palbo125mg for HR+HER2- locally advanced metastatic breast cancer","Oral dose of RLY-2608 in addition to fulvestrant and palbociclib 125mg as determined during Part 1 Dose Escalation.",[13,18,23],"Drug: Palbociclib 125mg",{"label":25,"type":10,"description":26,"interventionNames":27},"RLY-2608+fulvestrant+ribo400mg for HR+HER2- locally advanced metastatic breast cancer","Oral dose of RLY-2608 in addition to fulvestrant and ribociclib 400mg as determined during Part 1 Dose Escalation.",[13,18,28],"Drug: Ribociclib 400mg",{"label":30,"type":10,"description":31,"interventionNames":32},"RLY-2608+fulvestrant+ribo600mg for HR+HER2- locally advanced metastatic breast cancer","Oral dose of RLY-2608 in addition to fulvestrant and ribociclib 600mg as determined during Part 1 Dose Escalation.",[13,18,33],"Drug: Ribociclib 600mg",{"label":35,"type":10,"description":36,"interventionNames":37},"RLY-2608+fulvestrant+PF-07220060 100 mg for HR+ HER2- locally advanced or metastatic breast cancer","Oral dose of RLY-2608 in addition to fulvestrant and PF-07220060 100 mg as determined during Part 1 Dose Escalation",[13,18,38],"Drug: PF-07220060 100mg",{"label":40,"type":10,"description":41,"interventionNames":42},"RLY-2608+fulvestrant+PF-07220060 300 mg for HR+ HER2- locally advanced or metastatic breast cancer","Oral dose of RLY-2608 in addition to fulvestrant and PF-07220060 300 mg as determined during Part 1 Dose Escalation",[13,18,43],"Drug: PF-07220060 300 mg",[45,51,57,63,69,74,78],{"type":46,"name":47,"description":48,"armGroupLabels":49,"otherNames":50},"DRUG","RLY-2608","RLY-2608 is a mutant-selective, oral PI3Kα inhibitor.",[15,9,35,40,20,25,30],null,{"type":46,"name":52,"description":53,"armGroupLabels":54,"otherNames":55},"Fulvestrant","500 mg fulvestrant is administered intramuscularly on Cycle 1 Day 1, Day 15, and Day 1 of each subsequent cycle (where a cycle is 28 days).",[15,35,40,20,25,30],[56],"Faslodex",{"type":46,"name":58,"description":59,"armGroupLabels":60,"otherNames":61},"Palbociclib 125mg","125mg palbociclib is taken orally once daily for 28-day cycles that include 21 days of treatment followed by 7 days off treatment.",[20],[62],"Ibrance",{"type":46,"name":64,"description":65,"armGroupLabels":66,"otherNames":67},"Ribociclib 400mg","400mg ribociclib is taken orally once daily for 28-day cycles that include 21 days of treatment followed by 7 days off treatment.",[25],[68],"Kisqali",{"type":46,"name":70,"description":71,"armGroupLabels":72,"otherNames":73},"Ribociclib 600mg","600mg ribociclib is taken orally once daily for 28-day cycles that include 21 days of treatment followed by 7 days off treatment.",[30],[68],{"type":46,"name":75,"description":76,"armGroupLabels":77,"otherNames":50},"PF-07220060 100mg","PF-07220060 100 mg is taken orally twice daily at the same time with RLY-2608 during each 28-day cycle.",[35],{"type":46,"name":79,"description":80,"armGroupLabels":81,"otherNames":50},"PF-07220060 300 mg","PF-07220060 300 mg is taken orally twice daily at the same time with RLY-2608 during each 28-day cycle.",[40],[83],{"name":84,"role":85,"phone":86,"phoneExt":50,"email":87},"Relay Therapeutics Inc","CONTACT","617-322-0731","ClinicalTrials@relaytx.com",[89,103,113,123,133,143,153,163,173,183,189,199,209,219,229,238,244,250,260,270,279,289,299,305,315,327,337,343,355,364,373,384,395,402,411,417,426],{"facility":90,"status":91,"city":92,"state":93,"zip":94,"country":95,"countryCode":96,"cosmosGeoPoint":97,"geoPoint":102,"contacts":50},"The University of Arizona Cancer Center","RECRUITING","Tucson","Arizona","85724","United States","US",{"type":98,"coordinates":99},"Point",[100,101],-110.92648,32.22174,{"lat":101,"lon":100},{"facility":104,"status":91,"city":105,"state":106,"zip":107,"country":95,"countryCode":96,"cosmosGeoPoint":108,"geoPoint":112,"contacts":50},"University of California-San Diego","San Diego","California","90293",{"type":98,"coordinates":109},[110,111],-117.16472,32.71571,{"lat":111,"lon":110},{"facility":114,"status":91,"city":115,"state":116,"zip":117,"country":95,"countryCode":96,"cosmosGeoPoint":118,"geoPoint":122,"contacts":50},"HealthONE","Denver","Colorado","80218",{"type":98,"coordinates":119},[120,121],-104.9847,39.73915,{"lat":121,"lon":120},{"facility":124,"status":91,"city":125,"state":126,"zip":127,"country":95,"countryCode":96,"cosmosGeoPoint":128,"geoPoint":132,"contacts":50},"Yale University","New Haven","Connecticut","06510",{"type":98,"coordinates":129},[130,131],-72.92816,41.30815,{"lat":131,"lon":130},{"facility":134,"status":91,"city":135,"state":136,"zip":137,"country":95,"countryCode":96,"cosmosGeoPoint":138,"geoPoint":142,"contacts":50},"Florida Cancer Specialists","Orlando","Florida","32827",{"type":98,"coordinates":139},[140,141],-81.37924,28.53834,{"lat":141,"lon":140},{"facility":144,"status":145,"city":146,"state":136,"zip":147,"country":95,"countryCode":96,"cosmosGeoPoint":148,"geoPoint":152,"contacts":50},"Boca Raton Clinical Research (BRCR) Global","WITHDRAWN","Plantation","33322",{"type":98,"coordinates":149},[150,151],-80.23184,26.13421,{"lat":151,"lon":150},{"facility":154,"status":91,"city":155,"state":156,"zip":157,"country":95,"countryCode":96,"cosmosGeoPoint":158,"geoPoint":162,"contacts":50},"University of Chicago Medical Center","Chicago","Illinois","60637",{"type":98,"coordinates":159},[160,161],-87.65005,41.85003,{"lat":161,"lon":160},{"facility":164,"status":91,"city":165,"state":166,"zip":167,"country":95,"countryCode":96,"cosmosGeoPoint":168,"geoPoint":172,"contacts":50},"Community Health Network","Indianapolis","Indiana","46250",{"type":98,"coordinates":169},[170,171],-86.15804,39.76838,{"lat":171,"lon":170},{"facility":174,"status":91,"city":175,"state":176,"zip":177,"country":95,"countryCode":96,"cosmosGeoPoint":178,"geoPoint":182,"contacts":50},"Massachusetts General Hospital","Boston","Massachusetts","02114",{"type":98,"coordinates":179},[180,181],-71.05977,42.35843,{"lat":181,"lon":180},{"facility":184,"status":91,"city":175,"state":176,"zip":185,"country":95,"countryCode":96,"cosmosGeoPoint":186,"geoPoint":188,"contacts":50},"Dana-Farber Cancer Institute","02215",{"type":98,"coordinates":187},[180,181],{"lat":181,"lon":180},{"facility":190,"status":91,"city":191,"state":192,"zip":193,"country":95,"countryCode":96,"cosmosGeoPoint":194,"geoPoint":198,"contacts":50},"University of Michigan","Ann Arbor","Michigan","48109",{"type":98,"coordinates":195},[196,197],-83.74088,42.27756,{"lat":197,"lon":196},{"facility":200,"status":91,"city":201,"state":202,"zip":203,"country":95,"countryCode":96,"cosmosGeoPoint":204,"geoPoint":208,"contacts":50},"Washington University School of Medicine St. Louis","St Louis","Missouri","63110",{"type":98,"coordinates":205},[206,207],-90.19789,38.62727,{"lat":207,"lon":206},{"facility":210,"status":91,"city":211,"state":212,"zip":213,"country":95,"countryCode":96,"cosmosGeoPoint":214,"geoPoint":218,"contacts":50},"Renown Regional Medical Center","Reno","Nevada","89502",{"type":98,"coordinates":215},[216,217],-119.8138,39.52963,{"lat":217,"lon":216},{"facility":220,"status":91,"city":221,"state":222,"zip":223,"country":95,"countryCode":96,"cosmosGeoPoint":224,"geoPoint":228,"contacts":50},"Rutgers University","New Brunswick","New Jersey","08901",{"type":98,"coordinates":225},[226,227],-74.45182,40.48622,{"lat":227,"lon":226},{"facility":230,"status":91,"city":231,"state":231,"zip":232,"country":95,"countryCode":96,"cosmosGeoPoint":233,"geoPoint":237,"contacts":50},"NYU Langone","New York","10016",{"type":98,"coordinates":234},[235,236],-74.00597,40.71427,{"lat":236,"lon":235},{"facility":239,"status":91,"city":231,"state":231,"zip":240,"country":95,"countryCode":96,"cosmosGeoPoint":241,"geoPoint":243,"contacts":50},"Columbia University Herbert Irving Comprehensive Cancer Center","10032",{"type":98,"coordinates":242},[235,236],{"lat":236,"lon":235},{"facility":245,"status":91,"city":231,"state":231,"zip":246,"country":95,"countryCode":96,"cosmosGeoPoint":247,"geoPoint":249,"contacts":50},"Memorial Sloan Kettering","10065",{"type":98,"coordinates":248},[235,236],{"lat":236,"lon":235},{"facility":251,"status":91,"city":252,"state":253,"zip":254,"country":95,"countryCode":96,"cosmosGeoPoint":255,"geoPoint":259,"contacts":50},"Tennessee Oncology","Nashville","Tennessee","37203",{"type":98,"coordinates":256},[257,258],-86.78444,36.16589,{"lat":258,"lon":257},{"facility":261,"status":91,"city":262,"state":263,"zip":264,"country":95,"countryCode":96,"cosmosGeoPoint":265,"geoPoint":269,"contacts":50},"University of Texas Southwestern Medical Center","Dallas","Texas","75235",{"type":98,"coordinates":266},[267,268],-96.80667,32.78306,{"lat":268,"lon":267},{"facility":271,"status":91,"city":272,"state":263,"zip":273,"country":95,"countryCode":96,"cosmosGeoPoint":274,"geoPoint":278,"contacts":50},"The University of Texas M.D. Anderson Cancer Center","Houston","77030",{"type":98,"coordinates":275},[276,277],-95.36327,29.76328,{"lat":277,"lon":276},{"facility":280,"status":91,"city":281,"state":282,"zip":283,"country":95,"countryCode":96,"cosmosGeoPoint":284,"geoPoint":288,"contacts":50},"University of Utah- Huntsman Cancer Center","Salt Lake City","Utah","84112",{"type":98,"coordinates":285},[286,287],-111.89105,40.76078,{"lat":287,"lon":286},{"facility":290,"status":91,"city":291,"state":292,"zip":293,"country":95,"countryCode":96,"cosmosGeoPoint":294,"geoPoint":298,"contacts":50},"Inova Schar Cancer Center","Fairfax","Virginia","22031",{"type":98,"coordinates":295},[296,297],-77.30637,38.84622,{"lat":297,"lon":296},{"facility":300,"status":91,"city":291,"state":292,"zip":301,"country":95,"countryCode":96,"cosmosGeoPoint":302,"geoPoint":304,"contacts":50},"NEXT Virginia","22301",{"type":98,"coordinates":303},[296,297],{"lat":297,"lon":296},{"facility":306,"status":91,"city":307,"state":308,"zip":309,"country":95,"countryCode":96,"cosmosGeoPoint":310,"geoPoint":314,"contacts":50},"UW Carbone Cancer Center","Madison","Wisconsin","53792",{"type":98,"coordinates":311},[312,313],-89.40123,43.07305,{"lat":313,"lon":312},{"facility":316,"status":91,"city":317,"state":318,"zip":319,"country":320,"countryCode":321,"cosmosGeoPoint":322,"geoPoint":326,"contacts":50},"St Vincents Hospital","Sydney","New South Wales","2019","Australia","AU",{"type":98,"coordinates":323},[324,325],151.20732,-33.86785,{"lat":325,"lon":324},{"facility":328,"status":91,"city":329,"state":330,"zip":331,"country":320,"countryCode":321,"cosmosGeoPoint":332,"geoPoint":336,"contacts":50},"Peter MacCallum Cancer Center","Melbourne","Victoria","3000",{"type":98,"coordinates":333},[334,335],144.96332,-37.814,{"lat":335,"lon":334},{"facility":338,"status":91,"city":329,"state":330,"zip":339,"country":320,"countryCode":321,"cosmosGeoPoint":340,"geoPoint":342,"contacts":50},"The Alfred Hospital","3004",{"type":98,"coordinates":341},[334,335],{"lat":335,"lon":334},{"facility":344,"status":91,"city":345,"state":346,"zip":347,"country":348,"countryCode":349,"cosmosGeoPoint":350,"geoPoint":354,"contacts":50},"Centre Léon Bérard","Lyon","Auvergne-Rhône-Alpes","69008","France","FR",{"type":98,"coordinates":351},[352,353],4.84789,45.74906,{"lat":353,"lon":352},{"facility":356,"status":91,"city":357,"state":50,"zip":358,"country":348,"countryCode":349,"cosmosGeoPoint":359,"geoPoint":363,"contacts":50},"Institute Bergonié","Bordeaux","33076",{"type":98,"coordinates":360},[361,362],-0.58046,44.84124,{"lat":362,"lon":361},{"facility":365,"status":91,"city":366,"state":50,"zip":367,"country":348,"countryCode":349,"cosmosGeoPoint":368,"geoPoint":372,"contacts":50},"Gustave Roussy","Villejuif","94805",{"type":98,"coordinates":369},[370,371],2.35992,48.7939,{"lat":371,"lon":370},{"facility":374,"status":91,"city":375,"state":50,"zip":376,"country":377,"countryCode":378,"cosmosGeoPoint":379,"geoPoint":383,"contacts":50},"Istituto Europeo di Oncologia IRCCS","Milan","20141","Italy","IT",{"type":98,"coordinates":380},[381,382],12.59836,42.78235,{"lat":382,"lon":381},{"facility":385,"status":91,"city":386,"state":386,"zip":387,"country":388,"countryCode":389,"cosmosGeoPoint":390,"geoPoint":394,"contacts":50},"Vall d'Hebron Instituto de Oncologia","Barcelona","08035","Spain","ES",{"type":98,"coordinates":391},[392,393],2.15899,41.38879,{"lat":393,"lon":392},{"facility":396,"status":91,"city":386,"state":397,"zip":398,"country":388,"countryCode":389,"cosmosGeoPoint":399,"geoPoint":401,"contacts":50},"START Barcelona","Catalonia","08023",{"type":98,"coordinates":400},[392,393],{"lat":393,"lon":392},{"facility":403,"status":91,"city":404,"state":404,"zip":405,"country":388,"countryCode":389,"cosmosGeoPoint":406,"geoPoint":410,"contacts":50},"Instituto Valenciano de Oncologia","Valencia","46009",{"type":98,"coordinates":407},[408,409],-0.37966,39.47391,{"lat":409,"lon":408},{"facility":412,"status":91,"city":386,"state":50,"zip":413,"country":388,"countryCode":389,"cosmosGeoPoint":414,"geoPoint":416,"contacts":50},"Institut Catala D'Oncologia - Badalona (ICO Badalona)","08916",{"type":98,"coordinates":415},[392,393],{"lat":393,"lon":392},{"facility":418,"status":91,"city":419,"state":50,"zip":420,"country":388,"countryCode":389,"cosmosGeoPoint":421,"geoPoint":425,"contacts":50},"START Madrid - Hospital Fundacion Jimenez Diaz","Madrid","28040",{"type":98,"coordinates":422},[423,424],-3.70256,40.4165,{"lat":424,"lon":423},{"facility":427,"status":91,"city":419,"state":50,"zip":428,"country":388,"countryCode":389,"cosmosGeoPoint":429,"geoPoint":431,"contacts":50},"Hospital Universitario 12 de Octubre","28041",{"type":98,"coordinates":430},[423,424],{"lat":424,"lon":423},{"type":433,"investigatorFullName":50,"investigatorTitle":50,"investigatorAffiliation":50,"oldNameTitle":50,"oldOrganization":50},"SPONSOR","100455889","phase-1-first-in-human-study-of-mutant-selective-pi3k-inhibitor-rly-2608-as-a-single-agent-in-patients-with-advanced-solid-tumors-and-in-combination-with-endocrine-therapy---a-cdk46-or-cdk4-inhibitor-in-patients-with-advanced-solid-tumors-or-advanced-breast-cancer-100455889",false,"NCT05216432","First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +\u002F- a CDK4\u002F6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast Cancer","Key Inclusion Criteria\n\nPatient has ECOG performance status of 0-1\n\nOne or more documented primary oncogenic PIK3CA mutation(s) in blood and\u002For tumor per local assessment\n\nOther potentially oncogenic PIK3CA mutations may be considered but must be approved by the Sponsor prior to enrollment.\n\nPart 1 \\[Escalation\\] - Ability to provide archived tumor tissue or be willing to undergo pretreatment tumor biopsy to assess PIK3CA status retrospectively Part 2 \\[Expansion\\] - Submit tumor tissue prior to study drug initiation for determination of PIK3CA mutation retrospectively.\n\nKey Inclusion for RLY-2608 Single Agent Arm\n\n* \\[For Part 1: Escalation\\]: Evaluable disease per RECIST v1.1\n* \\[For Part 2: Expansion\\]: Measurable disease per RECIST v1.1\n* Disease that is refractory to standard therapy, intolerant to standard therapy, or has declined standard therapy.\n* Part 1- histologically or cytologically confirmed diagnosis of unresectable or metastatic solid tumor\n* Part 2 - Unresectable or metastatic solid tumor with PIK3CA mutation(s) and one of the following tumor types:\n\nGroup 1: clear cell ovarian cancer Group 2: head and neck squamous cell carcinoma Group 3: cervical cancer Group 4: other solid tumors, excluding colorectal, clear cell ovarian, head and neck squamous cell, and cervical cancers Group 5: unresectable or metastatic solid tumors with PIK3CA double mutations In addition, the SRC (with Sponsor approval) may choose to open additional group(s) of 20 participants to study the clinical activity, safety, and PK\u002FPD with other specified solid tumor types.\n\nKey Inclusion for Combination Arms:\n\n* Doublet combination arms \\[Part 1 and Part 2\\]: Evaluable disease per RECIST v1.1\n* Triplet combination arms:\n* \\[Part 1 and Part 2 Dose Expansion, Group 1\\]: Evaluable disease per RECIST.\n* \\[Part 2 Dose Expansion, Group 2\\]: Measurable disease per RECIST. Bone-only lytic or lytic\u002Fblastic disease with at least 1 measurable soft-tissue component per RECIST may be eligible.\n* \\[For Part 1 and Part 2\\]: Male or female with histologically or cytologically confirmed diagnosis of HR+, HER2- unresectable or metastatic breast cancer that is not amenable to curative therapy. Females may be postmenopausal, premenopausal, or perimenopausal. Premenopausal or perimenopausal females must have a histologically or cytologically confirmed diagnosis of HR+ HER2- locally advanced or metastatic breast cancer that is not amenable to curative therapy and must have initiated treatment with a gonadotropin-releasing hormone (GnRH) agonist at least 4 weeks prior to start of study drug with continuation of GnRH agonist for the duration of study treatment (GnRH agonist recommended for males).\n* Had previous treatment for breast cancer with: \\[Does not apply to triplet combination arms, Part 2 Dose Expansion, Group 2\\]:\n\n  1. ≤1 line of chemotherapy in the metastatic setting\n  2. ≥1 CDK4\u002F6 inhibitor in either the adjuvant and\u002For metastatic setting\n  3. ≥1 antiestrogen therapy in either adjuvant and\u002For metastatic setting, including, but not limited to, selective estrogen-receptor degraders (eg, fulvestrant), selective estrogen receptor modulators (eg, tamoxifen), and aromatase inhibitors (AI) (letrozole, anastrozole, exemestane), and\n  4. ≥1 PARP inhibitor, if appropriate, if documented germline BRCA1\u002F2 mutation Note: Systemic local, loco-regional, or adjuvant treatment with chemotherapy and PARP inhibitors is not to be included in enumeration or previous treatment\n\n\\[For double combination arm; Part 2 Dose Expansion, Group 2\\]: Received prior treatment with a PI3Kα, AKT, or mTOR inhibitor and discontinued the inhibitor due to intolerance and not disease progression, where intolerance is defined as treatment discontinuation due to treatment related AE (eg. hyperglycemia, rash, diarrhea, stomatitis) other than severe hypersensitivity reaction and\u002For life-threatening reactions, such as anaphylaxis and Stevens-Johnson syndrome.\n\n\\[For triple combination arms; Part 1 dose escalation\\]: Participants who had previous treatment for breast cancer with PI3Kα, AKT, mTOR inhibitors and discontiuned due to participant\u002Fphysician decision, intolerance, or disease progression will be considered.\n\n\\[For triple combination arms, Part 2 Dose Expansion, Group 2\\]: Participants must be intolerant to or have declined standard therapy for locally advanced or metastatic HR+\u002FHER2- PIK3CA-mutated breast cancer. Prior endocrine therapy and CDK4\u002F6inhibitors are allowed as follows:\n\n1. Participants must have progressed during (neo)adjuvant endocrine therapy or within12 months of completing (neo)adjuvant endocrine therapy with an AI or tamoxifen.\n2. If a CDK4\u002F6 inhibitor was included as part of (neo)adjuvant therapy, disease must have recurred\u002Fprogressed \\>12 months after completion of the CDK4\u002F6 inhibitor portion of (neo)adjuvant therapy\n\nKey Exclusion Criteria\n\nPrior treatment with:\n\n1. PI3Kα, AKT, or mTOR inhibitors (all arms except for doublet RLY-2608 + fulvestrant arm, Part 2, Group 2; and triplet combinations, Part 1 dose escalation).\n2. Immune checkpoint inhibitors.\n3. Triplet combinations RLY-2608 + CDK4 or CDK4\u002F6 inhibitor + fulvestrant, Part 2 expansion, Group 2 only:\n\ni. Prior systemic chemotherapy or antibody drug conjugate for locally advanced or metastatic disease. ii. Prior CDK2, CDK4, or CDK4\u002F6 inhibitor as treatment for locally advanced or metastatic disease.\n\niii. Prior treatment with fulvestrant or any selective ER degrader, with the exception of patients who have received fulvestrant or any selective ER degrader as part of neoadjuvant therapy only and with treatment duration ≤6 months.\n\nType 1 or Type 2 diabetes requiring antihyperglycemic medication, or fasting plasma glucose ≥140 mg\u002FdL and glycosylated hemoglobin (HbA1c) ≥7.0%.\n\nHistory of allergy or hypersensitivity to any components or excipients of PI3K inhibitors. For combination arms only: allergy or hypersensitivity to any components or excipients of fulvestrant, palbociclib, ribociclib, and\u002For PF-07220060 as appropriate for the combination.\n\nPast medical history of or ongoing ILD, or pneumonitis requiring intervention. Participants with past history of resolved Grade 1 pneumonitis may be considered, except in triple combination arms.\n\nThe following cardiac criteria:\n\n* Mean resting corrected QT interval (QTc) \\>460 msec\n* For triple combination arm with ribociclib: Mean QTcF ≥450 msec (this is what we confirmed is shown in the redacted version of the protocol.\n\nCNS metastases or primary CNS tumor that is associated with progressive neurologic symptoms","ALL","18 Years",{"count":443,"type":444},930,"ESTIMATED","INTERVENTIONAL",[447],"PHASE1","This is an open-label, FIH study designed to evaluate the maximum tolerated dose, recommended Phase 2 dose, safety, tolerability, PK, pharmacodynamics, and preliminary antineoplastic activity of RLY-2608, in advanced solid tumor patients with a Phosphatidylinositol-4,5-bisphosphate-3 kinase, catalytic subunit alpha (PIK3CA) mutation in blood and\u002For tumor per local assessment. The study will evaluate RLY-2608 as a single agent for patients with unresectable or metastatic solid tumors. It will also evaluate RLY-2608 in combination RLY-2608 + fulvestrant and in triple combination RLY-2608 + fulvestrant + CDK4\u002F6 inhibitor (palbociclib or ribociclib) or CDK4 inhibitor (PF-07220060) for patients with HR+ HER2- locally advanced or metastatic breast cancer. The RLY-2608 single agent arm, RLY-2608 + fulvestrant combination arm, and triple combination arms will have 2 parts: a dose escalation (Part 1) and a dose expansion (Part 2).",[450,451,452,453,454,455,456],"PIK3CA Mutation","Solid Tumor, Adult","HER2-negative Breast Cancer","Breast Cancer","Metastatic Breast Cancer","Advanced Breast Cancer","Unresectable Solid Tumor","2025-09-17",{"date":459,"type":460},"2025-09-22","ACTUAL",{"date":462,"type":460},"2021-12-08",{"date":464,"type":444},"2027-04-30",{"name":5,"class":6},37]